Table 1.
Baseline characteristics of dialysis patients—consisted of two groups according to serum aluminum (<20 [μg L-1] or ≥20 [μg L-1]).
| Total group | Aluminum <20 | Aluminum ≥20 | p Value | |
|---|---|---|---|---|
| (n = 99) | (n = 33) | (n = 66) | ||
| Sex-male | 54 (55%) | 19 (58%) | 35 (53%) | 0.669 |
| Age (year) | 54.0 ± 13.2 | 54.1 ± 12.5 | 53.6 ± 14.5 | 0.840 |
| Duration of dialysis(month) | 49.3 ± 31.0 | 49.7 ± 22.3 | 49.1 ± 34.7 | 0.926 |
| Hemodialysis/peritoneal dialysis | 92 (92.9) | 32 (97.0) | 60 (90.9) | 0.267 |
| Hematocrit (%) | 30.3 ± 5.6 | 30.7 ± 4.6 | 30.1 ± 6.0 | 0.655 |
| Calcium (mg dL-1) | 9.5 ± 1.1 | 9.6 ± 1.0 | 9.4 ± 1.1 | 0.573 |
| Phosphate (mg dL-1) | 5.7 ± 1.7 | 5.6 ± 1.9 | 5.7 ± 1.6 | 0.774 |
| Alkaline phosphatase (U L-1) | 95.2 ± 72.0 | 91.0 ± 49.4 | 97.3 ± 80.8 | 0.695 |
| Intact parathyroid hormone (pg mL-1) * | 669.4 ± 643.4 | 857.4 ± 678.8 | 578.3 ± 610.1 | 0.043 |
| Serum aluminum (μg L-1) ** | 33.1 ± 25.3 | 11.7 ± 5.3 | 43.7 ± 24.6 | <0.001 |
| Serum aluminum after DFO (μg L-1) ** | 86.0 ± 53.9 | 35.1 ± 21.2 | 111.5 ± 46.8 | <0.001 |
| ΔAluminum (μg L-1) ** | 53.0 ± 3.5 | 23.5 ± 16.9 | 67.7 ± 29.8 | <0.001 |
| Percentage of DFO positive** | 47 | 1/33 | 46/66 | <0.001 |
| Underlying disease (%) | ||||
| CGN | 28 | 10 | 18 | |
| CIN | 26 | 11 | 15 | |
| DM | 19 | 4 | 15 | |
| IgA nephropathy | 3 | 0 | 3 | |
| Nephrosclerosis | 8 | 1 | 7 | |
| Lupus | 3 | 0 | 3 | |
| Others | 12 | 5 | 7 |
DFO: desferroxime; CGN: chronic glomerulonephritis; CIN: chronic interstitial nephritis; DM: diabetes mellitus.
*<0.05; **<0.01.